On July 27, 2023, the Company announced decisions to reprioritize its areas of focus and to discontinue its clinical development of UpRi following an evaluation of top-line data from the Company’s UPLIFT Phase 2 clinical trial of UpRi in patients with platinum-resistant ovarian cancer, which did not meet its primary endpoint. In connection with these decisions, on July 26, 2023 the Company’s board of directors approved certain expense reduction measures, including a reduction of approximately 50% of the Company’s then-current total employee base (the "Restructuring"). Affected employees were eligible to receive severance and benefit payments, notice pay and outplacement services in connection with the reduction.

As of December 31, 2023, the Restructuring was substantially completed. Restructuring costs incurred are included within restructuring expenses on the consolidated statements of operations and comprehensive loss.


(in thousands)	Severance & Employee Related Costs		Contract Termination and Other Costs		Total Costs

Cumulative costs to date	$	6,924	$	1,789	$	8,713
Costs incurred during the year ended December 31, 2023	$	6,924	$	1,789	$	8,713

The following tables summarizes the charges incurred in connection with the Restructuring related to research and development activities and general and administrative activities:


(in thousands)	Severance & Employee Related Costs		Contract Termination Costs		Total Costs
Balance at December 31, 2022	$	—	$	—	$	—
Additional expense	6,924		372		7,296
Cash payments	(5,917)		—		(5,917)
Other adjustments	(252)		(80)		(332)
Balance at December 31, 2023	$	755	$	292	$	1,047